Inscobee Inc. bought $2.0M of APUS
owner at Apimeds Pharmaceuticals US, Inc.. 500,000 shares at an average of $4.00, traded May 12, 2025, filed May 14, 2025.
Score components
- +12Role10% owner
- +25Trade size$2.0M at market
- +6Relative to holdingsHoldings up 34%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -1.6%, 3m -12.9%, 6m +44.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001474506-25-000089, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 12, 2025 | POpen-market purchase Common Stock, par value $0.01 per share | +500,000 | $4.00 | $2.0M | 1,984,616 | May 14, 2025 |
| May 12, 2025 | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +182,002 | $2.60 | $473k | 4,316,618 | May 14, 2025 |
| May 12, 2025 | CConversion Common Stock, par value $0.01 per shareindirect: By Apimeds Inc. | +71,090 | $2.60 | $185k | 4,387,708 | May 14, 2025 |
| May 12, 2025 | CConversion Common Stock, par value $0.01 per share | +44,041 | $2.60 | $115k | 2,028,657 | May 14, 2025 |
| May 12, 2025 | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | CConversion Convertible Promissory Notederivativeindirect: By Apimeds Inc. | - | $0.00 | - | 0 | May 14, 2025 |
| May 12, 2025 | CConversion Convertible Promissory Notederivative | - | $0.00 | - | 0 | May 14, 2025 |
Related signals
Other insiders at Apimeds Pharmaceuticals US, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Apimeds Pharmaceuticals US, Inc. | Christopher Kim Chairman and CMO | $50k 27,500 shares | - | |
| 37Weak | Apimeds Pharmaceuticals US, Inc. | Jakap Koo director | $57k 28,500 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.